The feasibility of rapid genetic testing in patients undergoing percutaneous coronary intervention (PCI) and the comparison of the pharmacodynamic effects of prasugrel versus ticagrelor among carriers of cytochrome P450 2C19 loss-of-function alleles treated with PCI has been poorly explored. Rapid genetic testing using the Spartan assay was shown to be feasible and provides results in a timely fashion in a real-world setting of patients undergoing coronary angiography (n = 781). Among patients (n = 223, 28.5%), carriers of at least 1 loss-of-function allele treated with PCI (n = 65), prasugrel, and ticagrelor achieve similar levels of platelet inhibition. (A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function [NCT02065479]).
Keywords: ACS, acute coronary syndrome; CI, confidence interval; CYP, cytochrome P450; DAPT, dual antiplatelet therapy; HPR, high on-treatment platelet reactivity; LOF, loss of function; PCI, percutaneous coronary intervention; PD, pharmacodynamic; PRU, P2Y12 reaction unit; genotyping; percutaneous coronary intervention; pharmacodynamics; prasugrel; ticagrelor.
© 2020 The Authors.